红细胞生成素,重组

红细胞生成素,重组的相关文献在2000年到2020年内共计99篇,主要集中在内科学、外科学、药学 等领域,其中期刊论文99篇、专利文献332772篇;相关期刊54种,包括中华老年医学杂志、中华围产医学杂志、中华眼科杂志等; 红细胞生成素,重组的相关文献由396位作者贡献,包括孙衍伟、叶鸿瑁、姜秋颖等。

红细胞生成素,重组—发文量

期刊论文>

论文:99 占比:0.03%

专利文献>

论文:332772 占比:99.97%

总计:332871篇

红细胞生成素,重组—发文趋势图

红细胞生成素,重组

-研究学者

  • 孙衍伟
  • 叶鸿瑁
  • 姜秋颖
  • 孟岩
  • 彭志海
  • 徐英美
  • 李宾公
  • 李德天
  • 李慧
  • 李静
  • 期刊论文
  • 专利文献

搜索

排序:

年份

    • 杨柳冰
    • 摘要: 目的 观察血液净化联合重组促红细胞生成素(EPO)治疗对尿毒症患者骨代谢水平的影响.方法 选择2018年1月至2019年12月本院收治的60例尿毒症患者病理资料,随机将其分为观察组(30例)与对照组(30例),对照组患者采用血液净化治疗,观察组患者采用血液净化联合重组EPO治疗.比较两组患者治疗前后骨代谢指标变化情况、肾功能改善情况以及总有效率.结果 两组患者治疗前骨代谢指标比较,差异无统计学意义(P>0.05),治疗后观察组患者血清全段甲状旁腺素(iPTH)、骨碱性磷酸酶(BALP)、血钙、血磷指标分别为(120.83±13.26) μg/mL、(10.03±1.84) IU/L、(1.89±0.33) mmol/L、(1.32±0.46) mmol/L,均低于对照组,差异有统计学意义(P<0.05);观察组患者治疗后血尿素氮(BUN)、肌酐(Cr)水平分别为(10.58±2.56) mmol/L、(255.39±84.25) μmol/L,均低于对照组的(16.48±4.26) mmol/L、(364.15±67.24)μmol/L,差异有统计学意义(P<0.05),两组治疗前肾功能水平比较,差异无统计学意义(P>0.05);观察组患者治疗总有效率为93.3% (28/30),高于对照组的70.0%(21/30),差异有统计学意义(P<0.05).结论 血液净化联合重组EPO治疗尿毒症,对患者骨代谢指标改善作用显著,有利于降低肾损伤,疗效可靠,可予以推广.
    • 胡苗苗; 齐骥; 李慧; 赵倩倩; 魏琪琪; 李静
    • 摘要: Objective To systematically review the clinical efficacy and safety of early use of recombinant human erythropoietin (rHu-EPO) for neuroprotection in premature infants.Method From establishment of the databases to November 2017,clinical randomized controlled trials (RCTs) of early use of rHu-EPO in premature infants were searched on English databases (PubMed,Embase,Cochrane Collaboration) and Chinese databases (CNKI,SinoMed,Wanfang,and VIP Database).Patients receiving conventional therapy were assigned into control group,and patients receiving both conventional therapy and rHu-EPO were assigned into rHu-EPO group.rHu-EPO group was subdivided into high-dose continuous group and low-dose intermittent group.We retrieved the related literatures,evaluated the quality,and then performed Meta-analysis using RevMan 5.3 software.Result A total of 2 588 patients in 17 studies were included and analyzed.Compared with the control group,Meta-analysis showed that early use of rHu-EPO was more effective in improving NBNA scores at 40 weeks of corrected gestational age (cGA) (MD=2.46,95%CI 1.58~3.33,P<0.001),and high-dose continuous group was better than low-dose intermittent group (MD=3.19,95%CI 0.45~5.93,P=0.002;MD=2.22,95%CI 1.29~3.16,P<0.001).Low-dose intermittent use of rHu-EPO significantly increased mental development index (MDI) (MD=6.66,95%CI 0.80~12.51,P=0.010) and psychomotor development index (PDI) (MD=5.77,95%CI 4.00~7.55,P<0.001),and reduced the incidence of MDI<70 at cGA 18~22 months (OR=0.42,95%CI 0.27~0.67,P<0.001).As to the safety and side effects,treatment with rHu-EPO reduced the risk of necrotizing enterocolitis (OR=0.48,95%CI 0.31 ~0.72,P<0.001) and periventricular leukomalacia (OR=0.52,95%CI 0.35~0.75,P<0.001)without increasing the risk of bronchial dysplasia,patent ductus arteriosus,retinopathy in prematurity and intraventricular hemorrhage.Conclusion Current evidence shows that the early use of rHu-EPO in premature infants is relatively effective and safe,but multi-center RCTs are still needed.%目的 系统评价早期应用重组人促红细胞生成素(recombinant human erythropoietin,rHu-EPO)对早产儿神经系统保护的疗效和安全性.方法 检索PubMed、Embase、Cochrane图书馆、中国期刊全文数据库、中国生物医学文献数据库、万方及维普数据库有关早期应用rHu-EPO对早产儿神经系统保护的临床随机对照研究,检索时间自建库至2017年1l月.对照组常规治疗,rHu-EPO组常规治疗联合应用rHu-EPO,根据使用频次和剂量再分为大剂量连续应用亚组和小剂量间断应用亚组.对检索到的文献进行筛选和质量评价,应用RevMan 5.3软件进行Meta分析.结果 共纳入17篇文献,2 588例早产儿,其中rHu-EPO组1 314例,对照组1 274例.Meta分析显示,应用rHu-EPO能有效提高早产儿校正胎龄40周时的新生儿神经行为测定评分(MD=2.46,95%CI 1.58~3.33,P<0.001),且大剂量连续应用(MD=3.19,95%CI 0.45~5.93,P=0.002)较小剂量间断应用(MD=2.22,95%CI 1.29~3.16,P<0.001)效果更好;小剂量间断应用rHu-EPO可提高早产儿校正年龄18 ~ 24个月时的智力发育指数(MD=6.66,95%CI 0.80~12.51,P=0.010)和神经运动发育指数(MD=5.77,95%CI 4.00~7.55,P<0.001),降低智力发育指数<70的发生率(OR=0.42,95%CI 0.27~0.67,P<0.001);应用rHu-EPO能降低坏死性小肠结肠炎(OR=0.48,95%CI 0.31~0.72,P<0.010)和脑室周围白质软化(OR=0.52,95%CI 0.35~0.75,P<0.001)的发生风险,而且不增加支气管肺发育不良、动脉导管未闭、早产儿视网膜病和脑室内出血的发生风险.结论 早期应用rHu-EPO对早产儿神经系统有一定保护作用且安全,小剂量应用效果更显著,但仍需开展大量多中心的随机对照临床研究进一步证实.
    • 胡苗苗1; 齐骥1; 李慧2; 赵倩倩1; 魏琪琪2; 李静1
    • 摘要: 目的系统评价早期应用重组人促红细胞生成素(recombinant human erythropoietin,rHu-EPO)对早产儿神经系统保护的疗效和安全性。方法检索PubMed、Embase、Cochrane图书馆、中国期刊全文数据库、中国生物医学文献数据库、万方及维普数据库有关早期应用rHu-EPO对早产儿神经系统保护的临床随机对照研究,检索时间自建库至2017年11月。对照组常规治疗,rHu-EPO组常规治疗联合应用rHu-EPO,根据使用频次和剂量再分为大剂量连续应用亚组和小剂量间断应用亚组。对检索到的文献进行筛选和质量评价,应用RevMan 5.3软件进行Meta分析。结果共纳入17篇文献,2 588例早产儿,其中rHu-EPO组1 314例,对照组1 274例。Meta分析显示,应用rHu-EPO能有效提高早产儿校正胎龄40周时的新生儿神经行为测定评分(MD=2.46,95%CI 1.58~3.33,P<0.001),且大剂量连续应用(MD=3.19,95%CI 0.45~5.93,P=0.002)较小剂量间断应用(MD=2.22,95%CI 1.29~3.16,P<0.001)效果更好;小剂量间断应用rHu-EPO可提高早产儿校正年龄18~24个月时的智力发育指数(MD=6.66,95%CI 0.80~12.51,P=0.010)和神经运动发育指数(MD=5.77,95%CI 4.00~7.55,P<0.001),降低智力发育指数<70的发生率(OR=0.42,95%CI 0.27~0.67,P<0.001);应用rHu-EPO能降低坏死性小肠结肠炎(OR=0.48,95%CI 0.31~0.72,P<0.010)和脑室周围白质软化(OR=0.52,95%CI 0.35~0.75,P<0.001)的发生风险,而且不增加支气管肺发育不良、动脉导管未闭、早产儿视网膜病和脑室内出血的发生风险。结论早期应用rHu-EPO对早产儿神经系统有一定保护作用且安全,小剂量应用效果更显著,但仍需开展大量多中心的随机对照临床研究进一步证实。
    • 赵日红; 白纪红; 刘曼; 黄艳
    • 摘要: Objective To investigate the effects of recombinant human erythropoietin (rhEPO) on the expression of vascular endothelial growth factor (VEGF) protein and mRNA in lung tissue of premature rat model of the new type bronchopulmonary dysplasia (BPD).Methods Lipopolysaccharide (LPS) or PBS was injected into 60 pregnant rats on the 15th day of gestation.The premature rats by cesarean delivery on the 21th day of gestation were divided into 5 groups:PBS+ air group,PBS+ hyperoxia group,LPS+hyperoxia group,PBS+hyperoxia+rhEPO group,LPS+hyperoxia+rhEPO group.In rhEPO intervention groups,after 6 h exposure to hyperoxia,rhEPO (1 200 IU/kg) was administrated subcutaneously,once every other day for 7 times.The survival rate,body weight,lung weight and lung weight/body weight ratio and pathological changes of lung tissue were observed,the expression levels of VEGF protein and mRNA in the lung tissue were determined by Western blot and RT-PCR at the 1st,7th and 14th day after hyperoxia exposure.Results Compared with the PBS+air group,the survival rate and body weight were decreased,the lung weight was increased,the lung pathological damages were more serious,the expression levels of VEGF protein and mRNA in lung tissue were decreased after hyperoxia exposure.These changes were more notable in the LPS+hyperoxia group (P<0.05).The lung weight/body weight ratio showed an increasing tendency (P>0.05).The above indexes were improved after rhEPO intervention (P<0.05).Conclusion rhEPO could increase the survival rate and produce certain intervention and treatment effects by regulating the VEGF relative pathway in BPD model rats.%目的 观察重组人红细胞生成素(rhEPO)对新型支气管肺发育不良(BPD)早产鼠模型肺组织血管内皮生长因子(VEGF)蛋白及mRNA表达的影响.方法 60只定期受孕SD大鼠于孕第15天孕囊内注射脂多糖(LPS)或磷酸盐缓冲液(PBS),孕第21天剖宫娩出早产鼠,早产鼠于生后6h内分为5组:PBS+空气组、PBS+高氧组、LPS+高氧组、PBS+高氧+rhE-PO组、LPS+高氧+rhEPO组.rhEPO(1 200 IU/kg)干预组于高氧暴露6h后开始第1次背部皮下注射,隔天1次,共7次.分别在高氧暴露第1、7、14天处死早产鼠,观察各组生存率、体质量、肺质量并计算肺质量/体质量比值,观察肺组织病理变化,采用蛋白质印迹法(Western blot)和反转录PCR(RT-PCR)法检测肺组织VEGF蛋白及mRNA表达水平.结果 与PBS+空气组比较,经高氧干预后早产鼠生存率降低、体质量减轻、肺质量增加,病理损伤加重,肺组织VEGF蛋白及mRNA表达水平降低,并且以LPS+高氧组更明显(P<0.05),肺质量/体质量比值增加(P>0.05);rhEPO干预后上述指标得到相应改善(P<0.05).结论 rhEPO可能通过参与调解VEGF相关通路,对BPD模型早产鼠起到一定的干预和治疗作用,提高了生存率.
    • 胡苗苗; 齐骥; 李慧; 魏丽; 李静
    • 摘要: 目的 系统评价早期应用大剂量重组人促红细胞生成素(recombinant human erythropoietin,rHu-EPO)防治早产儿贫血的疗效和安全性.方法 检索Pubmed、Embase、Cochrane图书馆和中国期刊全文数据库、中国生物医学文献数据库、万方、维普数据库有关早期应用大剂量rHu-EPO防治早产儿贫血的临床随机对照试验,检索时间为建库至2017年2月,纳入研究对象为胎龄0.05);未增加早产儿坏死性小肠结肠炎、脑室周围白质软化和脑室内出血的风险.结论 早期应用大剂量rHu-EPO能有效防治早产儿贫血,但有增加早产儿视网膜病发生的风险.%Objective To evaluate the efficacy and safety of early use of high-dose rHu-EPO in the prevention of anemia in premature infants .Method Available data from clinical randomized controlled trials of early application of high-dose rHu-EPO to prevent premature infant anemia since database building till February 2017 were retrieved, which includes Pubmed, Embase, Cochrane Collaboration and CNKI , SinoMed, Wanfang, VIP.Premature infants less than gestational age of 37 weeks, with routine prevention of anemia as the control group and early combined use of high-dose rHu-EPO≥750 IU/( kg· w) as the treatment group.The relevant data from the literatures obtained were then screened and analyzed by the RevMan 5.3 software.Result A total of 1779 preterm infants from 21 articles including 898 cases of rHu-EPO treatment group and 881 cases in control group.Meta-analysis showed that rHu-EPO treatment group apparently increased the hemoglobin ( MD=27.42, 95%CI 20.01~34.84, P<0.001), hematocrit and reticulocyte count , reduced the blood transfusion. As to the risk of retinopathy of prematurity in rHu-EPO treatment group was significantly higher than that in the control group (RR=1.21, 95%CI 1.01~1.46, P=0.04), and reduced risks of bronchopulmonary dysplasia (RR=0.79, 95%CI 0.46 ~1.35, P =0.39) and patent ductus arteriosus ( RR =0.83, 95% CI 0.68 ~1.01, P=0.07) the difference, however, was not statistically significant, and there was no increasing risks of necrotizing enterocolitis , periventricular leukomalacia , intraventricular hemorrhage .Conclusion Early administration of high-dose of rHu-EPO can effectively prevent anemia in premature infants , but there is an increased risk of retinopathy of prematurity .
    • 胡苗苗12; 齐骥2; 李慧3; 魏丽2; 李静2
    • 摘要: 目的 系统评价早期应用大剂量重组人促红细胞生成素(recombinant human erythropoietin,rHu-EPO)防治早产儿贫血的疗效和安全性.方法 检索Pubmed、Embase、Cochrane图书馆和中国期刊全文数据库、中国生物医学文献数据库、万方、维普数据库有关早期应用大剂量rHu-EPO防治早产儿贫血的临床随机对照试验,检索时间为建库至2017年2月,纳入研究对象为胎龄〈37周早产儿,对照组常规防治贫血,治疗组早期应用rHu-EPO≥750 IU/(kg·周).对检索到的相关文献进行筛选和质量评价,采用RevMan5.3软件进行分析.结果 共纳入21篇文献,1779例早产儿,其中rHu-EPO治疗组898例,对照组881例.与对照组相比,rHu-EPO治疗组能有效升高血红蛋白(MD=27.42,95%CI 20.01-34.84)、红细胞压积和网织红细胞相对计数,明显减少输血率(RR=0.80,95%CI 0.72-0.88)、输血次数和输血量,但发生早产儿视网膜病的风险(RR=1.21,95%CI 1.01-1.46,P=0.04)增加;有减少支气管肺发育不良(RR=0.79,95%CI 0.46-1.35)和动脉导管未闭(RR=0.83,95%CI 0.68-1.01)的趋势,但差异无统计学意义(P〉0.05);未增加早产儿坏死性小肠结肠炎、脑室周围白质软化和脑室内出血的风险.结论 早期应用大剂量rHu-EPO能有效防治早产儿贫血,但有增加早产儿视网膜病发生的风险.
    • 朱波; 张砡; 王嵘; 卿恩明; 叶铁虎
    • 摘要: 目的 评价重组人促红细胞生成素(rHuEPO)对体外循环心脏瓣膜置换术患者脑损伤的影响.方法 择期拟行体外循环心脏瓣膜置换术的慢性瓣膜性心脏病患者45例,年龄36~ 62岁,体重42~ 92 kg,ASA分级Ⅱ或Ⅲ级,心功能分级Ⅱ或Ⅲ级,采用随机数字表法分为3组(n=15):对照组(C组)和不同剂量rHuEPO组(EPO1组和EPO2组).EPO1组于麻醉诱导前静脉注射rHuEPO40 IU/kg;EPO2组于麻醉诱导前静脉注射rHuEP0 80 IU/kg.分别于麻醉诱导前(T0,基础值)、气管插管后即刻(T1)、主动脉插管即刻(T2)、上下腔静脉插管即刻(T3)、CPB开始即刻(T4)、CPB中各指标最低值(T5)、复温至36.5°C(T6)、CPB停机即刻(T7)和停机后1 h(T8)时,记录双侧额叶脑氧饱和度(rSO2)、组织血红蛋白指数(THI)、氧合血红蛋白浓度变化(△O2Hb)、还原血红蛋白浓度变化(△HHb)和总血红蛋白浓度变化(△cHb);记录rSO2最低值≤50%和rSO2最低值较基础值降低幅度(△rSO2)≥20%的发生情况.分别于T0、T8和CPB停机后2 h(T9)时,采集静脉血样,采用ELISA法测定血清S100蛋白和神经元特异性烯醇化酶(NSE)的浓度.分别于术前1d和术后8d时采用简易精神状况检查法、数字广度试验、符号-数字模式测验、连线测验A型和Stroop字色干扰效应试验评估认知功能,记录术后认知功能障碍的发生情况.分别于术前1d和术后8d时,行自评抑郁量表评分和自评焦虑量表评分.结果 3组间各时点双侧rSO2、双侧△cHb、双侧rSO2最低值≤50%和术后认知功能障碍的发生率、自评抑郁量表评分和自评焦虑量表评分比较差异无统计学意义(P>0.05).与C组比较,EPO1组左侧△rSO2≥20%的发生率降低,T6,8时右侧△O2Hb升高,T9时血清NSE浓度降低,T8时血清S100蛋白浓度降低,术后8d时符号-数字模式测验完成个数增加,EPO2组T2、T3、T5、T7和T8时右侧THI降低,T2和T3时右侧△HHb升高,术后8d时Stroop字色干扰B完成时间缩短(P<0.05或0.01);与EPO1组比较,EP02组左侧△rSO2≥20%的发生率升高,T2-4和T6-8时右侧THI降低,T6,7时左侧△O2Hb和T8时右侧△O2Hb降低(P<0.05).结论 麻醉诱导前静脉注射rHuEPO40 IU/kg可减轻体外循环心脏瓣膜置换术患者脑损伤.%Objective To evaluate the effect of recombinant human erythropoietin (rHuEPO) on brain injury in the patients undergoing cardiac valve replacement with cardiopulmonary bypass (CPB).Methods Forty-five patients with chronic valvular heart disease,aged 36-62 yr,weighing 42-92 kg,of American Society of Anesthesiologists physical status Ⅱ or Ⅲ,with New York Heart Association of Ⅱ or Ⅲ,undergoing cardiac valve replacement with CPB,were randomly divided into 3 groups (n =15 each) using a random number table:control group (group C),and different doses of rHuEPO groups (EPO1 group,EPO2 group).In EPO1 and EPO2 groups,rHuEPO 40 and 80 IU/kg were injected intravenously before anesthesia induction,respectively.Before anesthesia induction (T0,baseline value),immediately after endotracheal intubation (T1),immediately after aortic cannulation (T2),immediately after cannulation of superior and inferior vena cava (T3),immediately after the beginning of CPB (T4),when each index was decreased to the minimal value during CPB (T5),after rewarming to 36.5 °C (T6),immediately after termination of CPB (T7),and at 1 h after termination of CPB (T8),regional cerebral oxygen saturation (rSO2),tissue hemoglobin index (THI),and changes in concentrations of oxyhemoglobin (△ O2Hb),deoxyhemoglobin (△ HHb) and total hemoglobin (△ cHb) in bilateral frontal lobes were recorded.The patients whose minimal rSO2 ≤ 50% and decrease in minimal rSO2 ≥ 20% of the baseline value (△rSO2) were recorded.At T0,T8 and 2 h after termination of CPB (T9),venous blood samples were taken for determination of serum concentrations of S100 protein and neuron-specific enolase (NSE) by ELISA.At 1 day before surgery and 8 days after surgery,the patient's cognitive function was assessed using Mini-Mental State Examination,the Digit Span subtest of the Wechsler Adult Intelligence Scale-Revised (WAIS-R),the Digit Symbol subtest of the WAIS-R,the Trailing Making Test (Part A)and the Stroop Color Word Interference Test,while depression and anxiety were assessed by Zung Self-Rating Depression Scale and Zung Self-Rating Anxiety Scale,respectively.The occurrence of postoperative cognitive dysfunction was recorded.Results There was no significant difference among the three groups in bilateral rSO2 and △ cHb,incidence of bilateral rSO2 ≤ 50% and postoperative cognitive dysfunction,Zung Self-Rating Depression Scale score,and Zung Self-Rating anxiety Scale score at each time point (P>0.05).Compared with group C,the incidence of left △ rSO2 ≥ 20% was significantly decreased,the right △ O2 Hb was increased at T6,8,the serum NSE concentrations were decreased at T9,the serum S100 protein concentrations were decreased at T8,and the number of the Digit Symbol subtest of the WAIS-R completed was increased in group EPO1,and right THI was significantly decreased at T2,T3,T5,T7 and T8,right △ HHb was increased at T2 and T3,and the completion time of Stroop color word interference test B was shortened at 8 days after surgery in group EPO2 (P<0.05 or 0.01).Compared with group EPO1,the incidence of left △rSO2 ≥ 20% was significantly increased,the right THI was decreased at T2-4 and T6-8,and the left △ O2 Hb at T6-7 and right △ O2 Hb at T8 were decreased in group EPO2 (P<0.05).Conclusion rHuEPO 40 IU/kg injected intravenously before induction of anesthesia can mitigate brain injury in the patients undergoing cardiac valve replacement with CPB.
    • 华威; 戚基萍; 吴鹤; 周敏; 刘微; 祝继原; 顾云鹤; 张振; 王宏达; 刘琪
    • 摘要: Objective To study biological effect of recombinant human erythropoietin ( RhEPO) on the expression of oligodendrocyte in the neuron glia antigen 2 ( NG2 ) , Nogo receptor-interacting protein 1 (LINGO-1), myelin basic protein (MBP) and myelin associated glycoprotein (MAG), and to explore the protective mechanism of RhEPO for oligodendrocyte after cerebral infarction.Methods Experimental rats were randomly divided into the treatment group ( RhEPO at a dose of 3 000 U/kg) or saline control group.Both groups received intraperitoneal injection of RhEPO after cerebral ischemia in 30 min, 3 h, 6 h, 12 h and 24 h, which was administered daily for 7 days.The modified neurological severity score ( mNSS) and histology were analyzed, and immunohistochemistry was used to detect the protein expression of NG2, MAG, MBP and LINGO-1.Results The overall mNSS of RhEPO treatment group significantly decreased compared with the saline control group on the seventh day after cerebral infarction ( P<0.05 ).Such treatment effect was more obvious in the treatment group at 30 min and 3 h ( P<0.01).Compared with the saline control group, the numbers of NG2 positive cells increased in RhEPO treatment group.In contrast, the expression of LINGO-1 protein significantly decreased (P<0.05), with a dramatic decrease observed at 30 min and 3 h ( P<0.01).However, the expression of MBP protein decreased more significantly in saline control group, while the level of the MAG protein expression increased.The differences were statistically significant ( P<0.05), especially at 30 min (P<0.01).Conclusions After cerebral ischemia, RhEPO promotes the proliferation of NG2 positive cells, and inhibits the expression of LINGO-1 and MAG proteins.RhEPO improves the proliferation and differentiation of oligodendrocyte precursor cells, which in turn protects neuronal function, particularly at the early phase of ischemia.%目的:探讨大鼠局灶性脑梗死后,重组人促红细胞生成素(RhEPO)对少突胶质细胞相关的神经胶质抗原2型硫酸软骨素糖蛋白( NG2)、Nogo受体作用蛋白( LINGO-1)、髓鞘碱性蛋白( MBP)和髓磷脂相关糖蛋白( MAG)表达情况的作用,通过以上蛋白的表达阐述RhEPO对于神经胶质细胞保护作用的机制。方法36只大鼠分为RhEPO治疗组(脑缺血后分别于30 min、3 h、6 h、12 h及24 h加入RhEPO 3000 U· kg-1· d-1腹腔注射,连用7 d,30只)、盐水对照组(于术后30 min给予腹腔注射生理盐水,7 d,每天1次,6只),利用神经功能缺损评分(mNSS)及免疫组织化学法检测相关蛋白NG2、MAG、MBP及LINGO-1表达情况。结果脑缺血后7 d,RhEPO治疗组较盐水对照组mNSS明显降低(P<0.05),以30 min及3 h给药组更为明显(P<0.01)。 RhEPO治疗各组较盐水对照组NG2阳性细胞数量明显增加, LINGO-1阳性细胞数目减少,差异有统计学意义( P<0.05),30 min及3 h组更显著(P<0.01)。较盐水对照组,各实验给药组MBP蛋白表达缺失程度减轻,而MAG蛋白表达减少,差异具有统计学意义(P<0.05),30 min给药组更显著(P<0.01)。结论脑缺血后,RhEPO促进NG2阳性细胞增殖,抑制LINGO-1、MAG蛋白的表达及髓鞘的脱失,进一步保护神经元提高神经功能恢复。早期应用,效果明显。
    • 陈艳霞; 吴险峰; 房向东; 秦晓华; 黄翀; 涂卫平
    • 摘要: 目的:探讨重组人红细胞生成素(rhEPO)对高糖诱导的正常人肾小管上皮(HK-2)细胞增殖及凋亡的影响及其可能机制。方法将体外培养的HK-2细胞按随机数字表法分为空白对照组、高糖诱导组(高糖终浓度为30 mmol/L)、甘露醇对照组(甘露醇浓度为24.5 mmol/L)、rhEPO对照组(rhEPO终浓度为20 U/mL)、不同浓度rhEPO干预组(高糖终浓度为30 mmol/L+rhEPO终浓度分别为5、10、20 U/mL)及Rho激酶抑制剂(Y27632)组(Y27632终浓度为30μmol/L+高糖终浓度为30 mmol/L),各组均刺激24 h。应用 RT-PCR 法检测各组 HK-2细胞 RhoA、ROCK1 mRNA的表达;MTT法测定细胞增殖,流式细胞技术分析细胞凋亡。结果高糖诱导组RhoA及ROCK1 mRNA表达较空白对照组显著升高(P<0.05),不同浓度rhEPO干预组RhoA mRNA及ROCK1 mRNA的表达较高糖诱导组显著减少(P<0.05),高糖诱导组及不同浓度rhEPO干预组RhoA mRNA与ROCK1 mRNA表达呈正相关。rhEPO可明显促进HK-2细胞增殖(P<0.05),而高糖可诱导正常人肾小管上皮细胞凋亡,加入不同浓度rhEPO或Y27632干预后,其凋亡明显受抑制(P<0.05),且在实验rhEPO浓度范围内,rhEPO促进增殖及抑制凋亡的作用呈现浓度依赖性。结论 rhEPO可促进高糖诱导的HK-2细胞增殖,抑制高糖诱导的HK-2细胞凋亡,其机制可能与阻断RhoA/ROCK信号通路有关。%Objective To study the effects of erythropoietin (rhEPO) in high glucose induced proliferation and apopto⁃sis of human kidney proximal tubular epithelial (HK-2) cells, and the possible mechanism thereof. Methods HK-2 cells cultured in vitro were divided into several groups randomly:blank control group, high glucose group, mannitol group, rhEPO control group, different concentrations of rhEPO treatment groups (5, 10, 20 U/mL) and Rho kinase group. The reverse tran⁃scription polymerase chain reaction (RT-PCR) was used to evaluate the mRNA levels of RhoA and ROCK after 24 hours. Tetrazolium salt method (MTT) was used to determine the cell proliferation. Cell apoptosis was detected by flow cytometry. Results Compared with blank control group the expression levels of RhoA and ROCK1 mRNA were significantly in⁃creased in high glucose group (P < 0.05). RhoA, ROCK1 mRNA expressions significantly decreased in rhEPO group than those of high glucose group (P<0.05). There was a positive correlation between the expression levels of RhoA mRNA and ROCK1 mRNA in high glucose group and rhEPO group. MTT method showed that rhEPO significantly promoted the prolifer⁃ation of HK-2 cells (P<0.05). Flow cytometry analysis showed that high glucose induced apoptosis in HK-2 cells, which was significantly inhibited in rhEPO group and Rho kinase group as compared to that of high glucose group in a concentra⁃tion dependent manner (P<0.05). Conclusion rhEPO can promote HK-2 cell proliferation and inhibit apoptosis, which may be related to RhoA/ROCK signaling pathway.
    • 董艳; 徐为人; 孔德新
    • 摘要: Erythropoietin (EPO) is an active glycoprotein synthesized by kidney. The physiological function of regulat⁃ing the synthesis of erythrocytes by EPO makes it as a clinical drug for treatment of anemia resulted from chronic kidney fail⁃ure. However, its short biological half-life makes frequent administration, which limits its wide clinical utility since the tough burden and pain on patients. Therefore, the development of EPO derivatives with good efficacy, less adverse reaction and long duration has been a hot spot in the field during several decades. There are currently many different variants of EPO derivatives including erythropoiesis stimulating agents (ESAs) on the market. This article aims to summarize the recent re⁃search progress in the development of erythropoietin derivatives, specially focusing on EPO mimetic peptides (EMP).%促红细胞生成素(Epo)是一种主要由肾脏合成并且分泌的活性糖蛋白,可刺激骨髓造血,主要用于治疗慢性肾功能衰竭导致的贫血性疾病,Epo口服不吸收,需静脉注射给药。由于其在人体内的生物半衰期较短,需要频繁注射,给患者在使用过程中带来很多不便并造成一定的经济负担。因此,开发疗效好、不良反应小且持续时间长的Epo一直是研究热点,目前市场上出现了多种新型的促红细胞生成素类药物,其中Epo拟肽的相关研究一直备受人们的关注,本文综述了近年来有关Epo拟肽类药物的研究情况。
  • 查看更多

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号